Chitosan Nanoparticles of Gamma-Oryzanol: Formulation, Optimization, and In vivo Evaluation of Anti-hyperlipidemic Activity.

Rawal T, Mishra N, Jha A, Bhatt A, Tyagi RK, Panchal S, Butani S

DOI: 10.1208/s12249-018-1001-8
Published: 2018 May
Container: AAPS PharmSciTech
Publisher: Not recorded
Open access: no

Credibility signals

serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1208/s12249-018-1001-8,
  title = {Chitosan Nanoparticles of Gamma-Oryzanol: Formulation, Optimization, and In vivo Evaluation of Anti-hyperlipidemic Activity.},
  author = {Rawal T and Mishra N and Jha A and Bhatt A and Tyagi RK and Panchal S and Butani S},
  year = {2018},
  journal = {AAPS PharmSciTech},
  doi = {10.1208/s12249-018-1001-8},
  url = {https://doi.org/10.1208/s12249-018-1001-8}
}

RIS

TY  - JOUR
TI  - Chitosan Nanoparticles of Gamma-Oryzanol: Formulation, Optimization, and In vivo Evaluation of Anti-hyperlipidemic Activity.
AU  - Rawal T
AU  - Mishra N
AU  - Jha A
AU  - Bhatt A
AU  - Tyagi RK
AU  - Panchal S
AU  - Butani S
PY  - 2018
JO  - AAPS PharmSciTech
DO  - 10.1208/s12249-018-1001-8
UR  - https://doi.org/10.1208/s12249-018-1001-8
ER  -

APA

T, R., N, M., A, J., A, B., RK, T., S, P., & S, B. (2018). Chitosan Nanoparticles of Gamma-Oryzanol: Formulation, Optimization, and In vivo Evaluation of Anti-hyperlipidemic Activity.. AAPS PharmSciTech. https://doi.org/10.1208/s12249-018-1001-8

Source records

pubmed · retrieved 2026-09-25T23:27:19.235Z
europe-pmc · retrieved 2026-09-25T23:27:19.261Z